Archive for 2007

  • 吉村和久、柴田潤二、畑田万紀子、山田裕子、増野弘幸、玉村啓和、松下修三:CD4 mimic small compoundとanti-HIV monoclonal antibodyのウイルス中和における相乗効果。第21回日本エイズ学会学術集会・総会. 2007.11.28-11.30. 広島.

  • 柴田潤二、吉村和久、松下修三:中和抗体高度抵抗性ウイルスを感受性にする変異はgp120三量体構造に影響を与える。第21回日本エイズ学会学術集会・総会. 2007.11.28-11.30. 広島.

  • 畑田万紀子,吉村和久,柴田潤二,松下修三:強力な抗HIV-1 gp120-V3抗体KD-247に対するHIV-1BaLの中和逃避のメカニズム解析. 第21回日本エイズ学会学術集会・総会. 2007.11.28-11.30. 広島.

  • 松下修三、西田吉辰、柴田潤二、畑田万紀子、吉村和久,: 長期非進行症例(LTNP)における交叉中和のメカニズムの研究 I; 中和単クローン抗体の作成と解析. 第21回日本エイズ学会学術集会・総会. 2007.11.28-11.30. 広島.

  • Matsushita S.:Development of broadly reactive neutralizing monoclonal antibody KD-247: implications for passive immunotherapy. Tentative Program for the 3rd Japan-Germany HIV/AIDS Symposium. Nov. 26, 2007. Hiroshima.

  • Yoshimura, K., Shibata, J., Honda A., Tamamura, H., and Matsushita S.: A potent neutralizing anti-V3 monoclonal antibody, KD-247 shows favorable synergism with other antiretrovirals, sCD4 and CD4 mimic small compound in vitro. 8th AIDS Seminar in Kumamoto. Sep 13-14, 2007. Aso, Kumamoto.

  • Hatada, M., Yoshimura K, Shibata J, Matsushita S. HIV-1BaL mutants escaping neutralization from a potent neutralizing anti-V3 monoclonal antibody KD-247. . 8th AIDS Seminar in Kumamoto. Sep 13-14, 2007. Aso, Kumamoto.

  • Shibata J, Yoshimura K, Matsushita S. :The single mutation in V2 domain affects quaternary structure of trimer gp120 and dramatically increases the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralizing antibodies. 8th AIDS Seminar in Kumamoto. Sep 13-14, 2007. Aso, Kumamoto.

  • Nishida,Y., Shibata, J., Yoshimura K., and Matsushita,S.: Broad neutralization against the HIV-1 subtype B panel of reference strains by human monoclonal antibodies established from an HIV-1infected long-term non-progressor. 8th AIDS Seminar in Kumamoto. Sep 13-14, 2007. Aso, Kumamoto.

  • Yoshimura K, Shibata J, Honda A,Koito A, Matsushita S. A potent neutralizing anti-V3 monoclonal antibody, KD-247 shows faborable synergism with other antiretrovirals,sCD4 and CD4 mimic small compound in vitro. The 4th IAS conference on HIV Pathogenesis, Treatment and Prevension, July 22-25, 2007

  • Matsushita S, Ikeda T, Shibata J, Koito K, Yoshimura K. Identification of integration sited of HIV-1 provirus; A possible target for the gene therapy for AIDS. 第13回日本遺伝子治療学会.2007.6.28-29、名古屋

  • Matsushita S., Ikeda, T, Shibata J., Honda A., Koito K, Yoshimura. K. Persistence of proviral DNA and the integration sites of HIV-1 in patients on prolonged and effective HAART. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Sydney, Australia. June. 22-25, 2007.

  • Ikeda T, Shibata J, Yoshimura K,Koito A, Matsushita S. Recurrent HIV-1 integration at the BACH2 locus in resting CD4+ T cell populations during effective HAART.J. Infect. Dis.195:716-725, 2007 .

  • Shibata J, Yoshimura K, Honda A.,Koito A, Murakami T. Matsushita S. Impact of V2 mutations for escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary HIV-1 isolate. J. Virol. 81:3757-3768,2007

  • Gatanaga H, Hayashida T, Tsuchiya K, Yoshino M, Kuwahara T, Tsukada H, Fujimoto K, Sato I, Ueda M, Horiba M, Hamaguchi M, Yamamoto M, Takata N, Kimura A, Koike T, Gejyo F, Matsushita S, Shirasaka T, Kimura S, Oka S.: Successful efavirenz dose reduction in HIV-1-infeccted individuals with cytochrome P450 2B6*6 and *26. Clinical Infectious Diseases., 45: 1230-1237, 2007.

  • Nakayama E.E., Carpentier W, Costagliola D., Shioda T., Iwamoto A., Debre P, Yoshimura K, Autran B, Matsushita S, Theodorou I. Wild type and H43Y variant of human TRIM5α show similar anti-human immunodeficiency virus type 1 activity both in vivo and in vitro. Immunogenetics 59:511-515, 2007.